California Is Putting $4 Million Behind Psychedelic Research for Veterans — and Sacramento Should Be at the Table

On November 10, California did something no other state has done at this scale.

The California Initiative to Advance Precision Medicine (CIAPM), part of the California Health and Human Services Agency, opened a Request for Applications for psychedelic research with veterans — $4 million in state funding, developed in coordination with the California Department of Veterans Affairs (CalVet). The funding was allocated by AB 113, a budget trailer bill signed earlier this year, and it follows two years of groundwork legislation: AB 2841 in 2024 removed barriers to psychedelic research in California, and AB 1103, signed in October 2025, expedited the state's research approval process.

For the MedStart community, this is worth a close read. It is one of the largest state-level research investments in this field, its structure is unusual in ways that reward community partnership, and our region — with UC Davis, the VA Northern California Health Care System, and a deep veteran community — is better positioned for it than most. But the first deadline is close, and the program's leadership rules mean most organizations reading this, including MedStart itself, cannot lead an application. Knowing your role early is the whole game.

What the Money Is

CIAPM will award $4 million total to support approximately two project teams, at up to $2 million per team, over a three- to four-year project term. Awards would start in August 2027 at the earliest and run to 2030 or 2031. Funds are disbursed monthly or quarterly by reimbursement.

Two teams. That is a small number, and it tells you something about the intent: CIAPM is not spreading seed grants around. It is funding a small number of substantial, well-partnered research programs that can produce real evidence.

What "Precision Medicine" Means Here

This is not psychedelic research in general. The program funds precision medicine in psychedelic research — work that moves toward matching treatment to the individual veteran rather than treating psychedelics as one-size-fits-all.

That shows up in a requirement worth underlining: every project must produce a precision medicine asset as a deliverable — new infrastructure, tools, measurements, or data that outlast the study itself. Projects should also engage and impact veterans directly and aim to reduce health disparities.

Qualifying projects take one of two shapes:

1. A new psychedelic-based study focused on veterans — a clinical trial, a clinical research study, or a study based on tribal practices and traditions.
2. An expansion of an existing psychedelic-based study — trial, research study, or tribal-practices study — that adds a greater focus on veterans.

Projects must take place in California and focus on people who live in California, though study populations are not limited to Californians only.

Who Has to Lead: The Co-Leadership Rule

This is the most important structural feature of the program, and it is deliberately designed.

Projects must be co-led by:

• A California nonprofit public or private academic research institution — this is the Primary Institution, the lead applicant; and
• At least one California-based nonprofit community partner — a community-based organization, veterans organization, community clinic, or a non-state public or tribal entity, including VA facilities administered by the Veterans Health Administration — that supports veterans and brings lived experience, expertise, and/or community or data assets to the team.

And one more rule with real teeth: at least one partner organization must have a minimum of five years of experience serving veterans.

CIAPM's language on this is pointed — partnerships should "break down silos between academic institutions and communities," and "partnership authenticity should be evident from project conception to completion and beyond." Reviewers will be looking for genuine co-leadership, not a university that went shopping for a veterans logo in December.

The honest consequence for our community: neither MedStart nor a member startup can lead one of these applications. This is an academic-led program. But as the next section explains, that is not the same as having no role.

The Timeline: Three Stages

The selection process has three stages, and the first one is deliberately light:

• RFA released: November 10, 2026
• Informational webinar and Q&A: December 2, 2026, 1:00 p.m. PT
• Letter of Intent due: December 18, 2026, 3:00 p.m. PT — required, but non-binding and not scored
• Initial Application due: February 19, 2027, 3:00 p.m. PT
• Finalists notified: April 23, 2027
• Full Application due (finalists): June 4, 2027, 3:00 p.m. PT
• Awards announced: July 2027 at the earliest
• Projects start: August 2027 at the earliest

Two details in that sequence matter for planning. First, partnerships are recommended but not required at the LOI stage — but they are required by the Initial Application stage in February. That gives teams a defined window between December and February to formalize a partnership, but realistically, the teams that win will be having those conversations now. Second, matching funds and in-kind contributions are not required, but they are "highly encouraged" and will be considered in selection — another reason to build the team early and broadly.

Where the MedStart Community Fits

If startups and ecosystem organizations cannot lead, what can they do? Several things, and they are the things this community is actually good at:

• Build the precision medicine asset. The required deliverable — tools, measurements, data infrastructure — is product work. A member company with a platform for patient-reported outcomes, biomarker measurement, trial operations, or longitudinal data could be exactly the partner an academic team is missing.
• Be the community connector. Academic institutions need authentic veteran-community partners, and those relationships cannot be manufactured in three weeks. Organizations in our network that already work with veterans — or can make credible introductions — have something genuinely scarce to offer before the December 18 LOI.
• Bring matching value. In-kind contributions count. Lab access, technology licenses, data assets, and personnel time all strengthen an application, and they are contributions a startup or an ecosystem organization can make without leading.

This is the connective work MedStart exists to do, and we are offering it concretely here: if you are a researcher forming a team, a veterans organization looking for an academic partner, or a company that could supply the precision-medicine tooling, reach out through MedStart. We will make the introductions we can, now, while introductions can still change an application's shape.

Why Sacramento, Specifically

Read the eligibility rules again and then look at our region. A California nonprofit academic research institution — UC Davis is in our backyard. A VA partner — the VA Northern California Health Care System, headquartered in Mather, serves veterans across our region. A large, engaged veteran population. A growing clinical research and life-science community that MedStart's members already work in every day.

None of that guarantees a Sacramento-led team wins one of roughly two awards statewide. But the ingredients the RFA asks for are unusually concentrated here, and statewide programs are regularly won by the regions that organize early and apply as genuine teams. December 18 is the first gate. The teams that clear it in good shape will be the ones that started forming in November.

What to Do This Month

1. Read the RFA on the California Grants Portal and confirm your organization's role in the structure — lead, co-lead, or partner.
2. Attend the December 2 webinar (1:00 p.m. PT). It is the one scheduled chance to hear CIAPM's intent directly and ask questions before the LOI.
3. Start the partnership conversation now if there is any chance you will be on a team. Remember the five-year rule: your team needs at least one partner with five or more years of experience serving veterans.
4. Submit the Letter of Intent by December 18, 3:00 p.m. PT. It is non-binding and not scored — there is almost no downside to filing it and keeping your options open into February.

California has decided that veterans' health is where psychedelic research should prove itself, and it has put real money and a serious structure behind that decision. Our region has the researchers, the VA presence, and the veteran community to compete for it. Let's make sure Sacramento is at the table.

---

Sources

• California Grants Portal — “Psychedelic Precision Medicine Research with Veterans” — California Initiative to Advance Precision Medicine (CIAPM), California Health and Human Services Agency
• Office of the Governor — “California Announces Funding for Psychedelic Treatment Research to Improve Veterans’ Health” (November 10, 2026)
• California Initiative to Advance Precision Medicine (CIAPM) — program website, California Health and Human Services Agency

Details checked against the California Grants Portal listing and the Governor's announcement on November 13, 2026. Programs change — always confirm details on the official program page before applying. This post is for information only and is not funding, legal, or medical advice.